Cyclin-dependent kinase inhibitors closer to market launch?

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 8, 2013, Pages 945-963

  Galons, Hervé ^a,b   Oumata, Nassima ^b   Gloulou, Olfa ^a   Meijer, Laurent ^b  

^a Centre de Perharidy   (France)

^b INSERM   (France)

Author keywords

Cancer; Cell cycle; Cyclin dependent kinase

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; AT 7519; BAY 1000394; CYCLIN DEPENDENT KINASE INHIBITOR; DANSYL CHLORIDE; DINACICLIB; DOXORUBICIN; ERLOTINIB; FASCAPLYSIN; FLAVONE; FLAVONOID; FLAVOPIRIDOL; GEMCITABINE; IMIDAZOPYRIDINE DERIVATIVE; INDIRUBIN; LAPATINIB; MILCICLIB; P 276 00; PHA 648125; POLYPHENOL; PURINE DERIVATIVE; PURVALANOL; PYRIDINE DERIVATIVE; RGB 286638; ROSCOVITINE; UNCLASSIFIED DRUG; WOGONIN;

ACUTE MONOCYTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; CHIRAL CHROMATOGRAPHY; CHRONIC LYMPHATIC LEUKEMIA; DRUG INDICATION; DRUG MARKETING; DRUG STRUCTURE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR GROWTH; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC;

EID: 84880669791     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.789861     Document Type: Review

References (87)

1. Ward RA, Goldberg F Drug discovery and non-human kinomes In: Ward RA, Goldberg F, editors Kinase drug discovery RSC Publishing, UK; 2012 p 262-85
2. Fedorov O, Muller S, Knapp S The (un)targeted cancer kinome Nat Chem Biol 2010;6:166-9
3. Zhang HH, Zhang XQ, Wang WY, et al Increased synaptophysin is involved in inflammation-induced heat hyperalgesia mediated by cyclin-dependent kinase 5 in rats PLoS One 2012;7:e46666
4. Frontini M, Kukalev A, Leo E, et al The CDK subunit CKS2 counteracts CKS1 to control cyclin A/CDK2 activity in maintaining replicative fidelity and neurodevelopment Dev Cell 2012;23:356-70
5. Cicenas J, Valius M The CDK inhibitors in cancer research and therapy J Cancer Res Clin Oncol 2011;137:1409-18
6. Chang KH, de Pablo Y, Lee HP, et al Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease J Neurochem 2010;113:1221-9
7. Koedel U, Frankenberg T, Kirschnek S, et al Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis PLoS Pathog 2009;5:e1000461
8. Menn B, Bach S, Blevins TL, et al Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models PLoS One 2010;5:e12117
9. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, et al CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases Kidney Int 2008;73:684-90
10. Krystof V, Chamrad I, Jorda R, et al Pharmacological targeting of CDK9 in cardiac hypertrophy Med Res Rev 2010;30:646-66
11. Kashanchi F, Kehn-Hall K Cyclin dependent kinases as attractive targets to prevent transcription from viral genomes Curr Pharm Des 2009;15:2520-32
12. Malumbres M, Barbacid M Cell cycle, CDKs and cancer: a changing paradigm Nat Rev Cancer 2009;9:153-66
13. Slovackova J, Smarda J, Smardova J Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53 Neoplasma 2012;59:606-12
14. Ramaswamy B, Phelps MA, Baiocchi R, et al A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors Invest New Drugs 2012;30:629-38
15. Le Tourneau C, Faivre S, Laurence V, et al Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies Eur J Cancer 2010;46:3243-50
16. Tong WG, Chen R, Plunkett W, et al Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma J Clin Oncol 2010;28:3015-22
17. Leonard JP, LaCasce AS, Smith MR, et al Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma Blood 2012;119:4597-607
18. Mahadevan D, Plummer R, Squires MS, et al A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors Ann Oncol 2011;22:2137-43
19. Siemeister G, Lucking U, Wengner AM, et al BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono-and in combination treatment upon oral application Mol Cancer Ther 2012;11:2265-73
20. Hirte HW, Raghunadharao D, Baetz T, et al A phase 1 study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms J Clin Oncol ASCO Annual Meeting Proceedings Part I 2007;18S:14117
21. de Bruijn P, Moghaddam-Helmantel IM, de Jonge MJ, et al Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry J Pharm Biomed Anal 2009;50:977-82
22. Stone A, Sutherland RL, Musgrove EA Inhibitors of cell cycle kinases: recent advances and future prospects as cancertherapeutics Crit Rev Oncog 2012;17:175-98
23. Pevarello P, Villa P Cyclin-dependent kinase inhibitors: a survey of the recent patent literature Expert Opin Ther Pat 2005;15:675-703
24. Galons H, Oumata N, Meijer L Cyclin-dependent kinase inhibitors: a survey of recent patent literature Expert Opin Ther Pat 2010;20:377-404
25. Aggennix Aminoindeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases useful for the treatment of alopecia, viral infections and hyperproliferative disorders A pharmaceutical composition and uses related thereto SG173222; 2011
26. Amgen Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 WO129344; 2012
27. Anygen Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors WO096676; 2011
28. Liao XM, Leung KN Indirubin-3'-oxime induces mitochondrial dysfunction and triggers growth inhibition and cell cycle arrest in human neuroblastoma cells Oncol Rep 2013;29:371-9
29. Vougogiannopoulou K, Ferandin Y, Bettayeb K, et al Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase-3 alter circadian period J Med Chem 2008;51:6421-31
30. Astex Combinations of pyrazole derivatives for the inhibition of CDKs and GSKs US021420; 2010
31. Astex Pharmaceutical compounds US0004243; 2010
32. Astex Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases EP2395000; 2011
33. Howard S, Berdini V, Boulstridge JA Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity J Med Chem 2009;52:379-88
34. Bayer Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors the production thereof, and use as a medicine US0251222; 2011
35. Bayer Schering Pharma Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine EP2179993; 2010
36. Bayer Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors the production thereof, and use as medicine US0294838; 2011
37. Cyclacel Combinaison of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders US0143350; 2010
38. Wilson SC, Atrasha B, Barlow C Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors Bioorg Med Chem Lett 2011;19:6949-65
39. Cyclacel Crystalline forms of a purine derivative WO089401; 2011
40. Gilead Imidazolyl pyrimidine inhibitor compounds WO009139; 2010
41. Gilead Oxindolyl inhibitor compounds WO009166; 2010
42. Gilead Fused heterocyclic inhibitor compounds WO009155; 2010
43. Gilead Imidazole derivatives and their use as modulators of cyclin dependent kinase WO125402; 2010
44. Hoffman la roche Benzotriazole kinase modulators WO028860; 2008
45. Nerviano CDK inhibitor in the treatment of mesothelioma WO058006; 2010
46. Nerviano Use of a CDK inhibitor for the treatment of glioma WO012733; 2010
47. Nerviano Use of a CDK inhibitor for the treatment of thymona WO106028; 2010
48. Nissan Alpha-amino acid derivatives and medicaments containing the same as an active ingredient US7,879,887; 2011
49. Novartis Organic compounds and their use WO079933; 2008
50. Novartis Pyrazinylpyridines useful for treatment of proliferative diseases WO0026904; 2011
51. Novartis and Astex Pyrrolopyrimidine compounds as CDK inhibitors WO020675; 2010
52. Novartis and Astex Pyrrolopyrimidine compounds as CDK inhibitors of CDK4/6 WO101409; 2011
53. Piramal A synergistic pharmaceutical combination for the treatment of pancreatic cancer WO123889; 2012
54. Piramal Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment cancer CA2761182; 2010
55. Schering New pyrazolopyrimidines as cyclin-dependent kinase inhibitor JP2010180235; 2010
56. CNRS Perharidines as CDK inhibitors US020065; 2010
57. CNRS Method if treatment of polycystic disease and chronic lymphocytic leukemia WO103473; 2010
58. Bettayeb K, Oumata N, Echalier A CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases Oncogene 2008;27:5797-807
59. Bukanov NO, Moreno SE, Natoli TA CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD Cell Cycle 2012;11:4040-6
60. CNRS Pyrazolo[1,5-A]triazine derivatives, preparation thereof, and therapeutic use thereof US184557; 2012
61. Dalian University Cyclin dependent kinases inhibitor scutellaria flavonoid organic amine derivatives, preparation method and application thereof CN101591322; 2009
62. Georgetown University Fluorescent cdk inhibitors for treatment of cancer WO019967; 2010
63. Ringer L, Sirajuddin P, Yenugonda VM VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells Bioorg Med Chem 2011;19:2714-25
64. Hong Kong University CDK5 Inhibitors and therapeutic uses thereof US270821; 2012
65. Nottingham University Compounds for treating proliferative disorders WO161446; 2011
66. Univerzita Palackeho Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds WO085924; 2010
67. Krystof V, McNae IW, Walkinshaw MD, et al Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor Cell Mol Life Sci 2005;62:1763-7168 Tokyo University Inhibition of replication of hepatitis C virus by CDK inhibitor WO 013466; 2010
68. Massard C, Soria JC, Anthoney DA A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors Cell Cycle 2011;10:963-70
69. Betzi S, Alam R, Martin M Discovery of a potential allosteric ligand binding site in CDK2 ACS Chem Biol 2011;6:492-501
70. Fischmann TO, Hruza A, Duca JS Structure-guided discovery of cyclin-dependent kinase inhibitors Biopolymers 2008;89:372-9
71. Bettayeb K, Oumata N, Echalier A, et al C&R8 a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases Oncogene 2008;27:5797-807
72. Bettayeb K, Baunbæk D, Delehouze C CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells Genes Cancer 2010;1:369-80
73. Squires S, Cooke Lock V AT7519 a cyclin-dependent kinase inhibitor exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples Mol Cancer Ther 2010;9:920-8
74. Parry D, Timothy Guzi T, Shanahan F Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor Mol Cancer Ther 2010;9:2344
75. Malumbres M, Pevarello P, Barbacid M.
76. Guha M Cyclin dependent kinase inhibitors move into Phase III Nature Rev Drug Discovery 2012;11:892-4
77. Nair BJ, Vallabhanen S, Tekmal RR Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells Breast Cancer Res 2011;13:R80
78. Booher R, Hirsch H, Peter Strack P Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment Cancer Res 2012;72(Suppl 8):abstract 3063
79. Horiuchi D, Kusdra L, Huskey NE MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition J Exp Med 2012;209:679-96
80. Nanos-Webb A, Jabbour NA Targeting low molecular weight cyclin E (LMW-E) in breast cancer Breast Cancer Res Treat 2012;132:575-88
81. Feldmann G, Mishra A, Bisht S Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models Cancer Biol Ther 2011;12:598-609
82. Subramaniam D, Periyasamy G, Ponnurangam S CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis Mol Cancer Ther 2012;11:1598-608
83. Winter GE, Rix U, Carlson SM Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML Nature Chem Biol 2012;8:905-12
84. http://www.cyclacel.com/research-programs-oncology-cyc202 shtml
85. Martin KL, Hill GA, Klein RR Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model PLoS ONE 2012;7:e51363
86. Lange CA, Yee D K4/6 inhibitor PD-0332991, in combinaison with the aromatase inhibitor LetrozoleKilling the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer Endocr Relat Cancer 2011;18:19-24
87. Flynn JM, Jones JA, Andritsos L Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL J Clin Oncol 2011;29(Suppl):abstract 6623